Formulation and In vitro Interaction of Rhodamine-B Loaded PLGA Nanoparticles with Cardiac Myocytes by Antranik Jonderian & Rita Maalouf
fphar-07-00458 December 2, 2016 Time: 15:36 # 1
ORIGINAL RESEARCH
published: 06 December 2016
doi: 10.3389/fphar.2016.00458
Edited by:
Firas H. Kobeissy,
University of Florida, USA
Reviewed by:
Angelo Leone,
University of Palermo, Italy
Shankar Munusamy,
Qatar University, Qatar
*Correspondence:
Rita Maalouf
rita.maalouf@ndu.edu.lb
Specialty section:
This article was submitted to
Predictive Toxicology,
a section of the journal
Frontiers in Pharmacology
Received: 04 September 2016
Accepted: 14 November 2016
Published: 06 December 2016
Citation:
Jonderian A and Maalouf R (2016)
Formulation and In vitro Interaction
of Rhodamine-B Loaded
PLGA Nanoparticles with Cardiac
Myocytes. Front. Pharmacol. 7:458.
doi: 10.3389/fphar.2016.00458
Formulation and In vitro Interaction
of Rhodamine-B Loaded PLGA
Nanoparticles with Cardiac Myocytes
Antranik Jonderian and Rita Maalouf*
Department of Sciences, Notre Dame University – Louaize, Zouk Mosbeh, Lebanon
This study aims to characterize rhodamine B (Rh B) loaded poly(D,L-lactide-co-glycolide;
PLGA) nanoparticles (NPs) and their interactions with cardiac myocytes. PLGA NPs
were formulated using single emulsion solvent evaporation technique. The influence
of varying parameters such as the stabilizer concentration, the sonication time, and
the organic to aqueous ratio were investigated. The diameter, the dispersity, the
encapsulation efficiency and the zeta potential of the optimized NPs were about 184 nm,
0.19, 40% and−21.7 mV, respectively. In vitro release showed that 29% of the Rh B was
released within the first 8 h. Scanning electron microscopy measurements performed
on the optimized NPs showed smooth surface and spherical shapes. No significant
cytotoxic or apoptotic effects were observed on cardiac myocytes after 24 and 48 h of
exposure with concentrations up to 200 µg/mL. The kinetic of the intracellular uptake
was confirmed by confocal microscopy and cells took up PLGA NPs within the 1st
hours. Interestingly, our data show an increase in the NPs’ uptake with time of exposure.
Taken together, we demonstrate for the first time that the designed NPs can be used as
potential probes for drug delivery in cardiac myocytes.
Keywords: PLGA, nanoparticles, rhodamine B, cardiac myocytes, cytotoxicity
INTRODUCTION
The use of nanotechnology in medicine is considered to be a breakthrough in the field of
disease treatments. Biodegradable NPs have been used in various medical applications to carry
diagnostic imaging agents and to achieve therapeutic drug delivery (Parveen et al., 2012).
Due to their versatility and their wide range of properties, they act as potential carriers for
the controlled delivery of several types of drugs as they promise to overcome many of the
obstacles inherently associated with their administration (Hans and Lowman, 2002; Panyam
and Labhasetwar, 2003; Mahapatro and Singh, 2011). The targeted delivery of the encapsulated
molecules allows the increase of the concentration of the drug in some parts of the body
relative to others, the maintenance of optimum therapeutic drug concentration for sustained
periods of time and the reduction of the frequency of dosages taken by the patient. Also,
they extend the drug circulation lifetime and reduce side effects (Manoochehri et al., 2013;
Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; DCM, dichloromethane; DLS, dynamic light scattering; DMEM,
Dulbecco’s Modified Eagle Medium; DPBS, Dulbecco’s phosphate buffer saline; EE, encapsulation efficiency; HG, high
glucose; NPs, nanoparticles; PBS, phosphate buffer saline; PDI, polydispersity index; PGA, poly (glycolic acid); PLA, poly
(lactic acid); PLGA, poly(D,L-lactide-co-glycolide); PVA, poly (vinyl alcohol); Rh B, rhodamine B; SEM, scanning electron
microscopy.
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Cooper and Harirforoosh, 2014; Bandyopadhyay et al., 2015).
Various types of NPs have been investigated for drug delivery
applications. Polyketal-based NPs were used to deliver drug
and RNA silencing, respectively (Aso et al., 2007; Gray et al.,
2011; Somasuntharam et al., 2013). On the other side, Xie et al.
(2013) developed a carrier based on dextran-co-gelatin NPs
to deliver vascular endothelial growth factor for the treatment
of peripheral artery disease. Other researchers used micelles,
liposomes, as well as gold NPs for drug delivery (Suarez et al.,
2015). However, PLGA NPs are most extensively researched
owing to their biocompatibility and biodegradability. PLGA
degrades by hydrolysis through cleavage of its backbone ester
linkages forming biologically compatible and metabolizable
moieties (lactic acid and glycolic acid). They can be processed by
the body through the citric acid cycle and eliminated as carbon
dioxide and water.
Degradation rates from months to years can be attained by
tuning relevant parameters such as the molecular weight of
PLGA, ratio of lactide to glycolide, drug content and nanoparticle
size. PGA is hydrophilic and a highly crystalline polymer with a
relatively fast degradation rate (Park, 1995). For instance, when
co-polymerized with PLA, it increases its rate of hydration and
hydrolysis. Thus, the higher content of PGA leads to a faster
degradation with an exception of the 50/50 PLA/PGA blend that
exhibits the quicker decomposition rate (Gentile et al., 2014). It
has been also reported that high surface area to volume ratio
leads to high degradation rate of the matrix (Makadia and Siegel,
2011). Furthermore, an optimal drug release rate from PLGA
is very crucial to achieve a sustained delivery. Larger particles
have smaller initial burst release and longer sustained release than
smaller particles (Mahapatro and Singh, 2011). Moreover, NPs
having higher drug content possess a larger initial burst release
than those having lower content because of their smaller polymer
to drug ratio (Hans and Lowman, 2002).
Despite the extensive literature related to PLGA NPs use,
whether described in cardiac tissues or other organ tissues (Yi
et al., 2006; Chang et al., 2013; Navarro et al., 2014), yet, to
our knowledge, this is the first study where RhB-loaded PLGA
NPs were prepared as models to study their kinetic uptake
in primary cardiac myocytes in vitro. Importantly, PLGA NPs’
cytotoxicity was also studied in comparison to HG toxicity in the
same type of cells, mimicking a diabetic milieu. The designed
NPs will pave the way for future synthesis of targeted drug-
loaded NPs for the treatment of diabetic cardiomyopathy and
various heart diseases. Hyperglycemia is a major risk factor in the
development of diabetic cardiomyopathy, comprising functional
and structural abnormalities in the heart, including diastolic
and/or systolic dysfunction, altered cardiac contractility, cell
hypertrophy, apoptosis and interstitial fibrosis.
MATERIALS AND METHODS
Reagents and Chemicals
Poly(D,L-lactide-co-glycolide; lactide:glycolide molar ratio 50:50,
MW 30,000–60,000), PVA (87–89% hydrolyzed, MW 13,000–
23,000), Rh B (MW 479.01), and mannitol were purchased
from Sigma-Aldrich. DCM was purchased from VTC. All other
chemicals and solvents were of HPLC grade. The primary
rat cardiac myocytes were purchased from Lonza and grown
as described by the manufacturer protocol (CM561-6 03/13).
In brief cell were grown in Rat Cardiac Myocyte Growth
Media containing Horse Serum, Fetal Bovine Serum [FBS],
and Gentamicin/Amphotericin-B [GA] and incubated at 37◦C
in a 5% CO2 incubator. Before the experiments cells were
serum deprived for 12 h then treated with HG, mannitol
or the different concentration of the RhoB-loaded PLGA
NPs.
Preparation of Rhodamine-Loaded
Nanoparticles
Nanoparticles loaded with Rh B were fabricated by a single
emulsion-solvent evaporation technique (Scholes et al., 1993).
Briefly, a solution of 50 mg of PLGA in 1 mL of DCM
containing 0.01 mg/mL Rh B, was mixed with 10 mL of
2.5% PVA aqueous solution. This mixture was sonicated using
a probe sonicator (Qsonica) set at 20 W for 10 min to
produce the oil-in-water emulsion. The organic phase was
evaporated during 45 min using a rotary evaporator under
partial vacuum. The NPs were recovered by ultracentrifugation
at 72,000.00 × g for 10 min and washed three times
with deionized water in order to remove free and surface
adsorbed Rh B. The washing solutions were eliminated by
centrifugation as described previously. The purified NPs were
lyophilized. The supernatant removed in the first step and the
washing solutions were combined together and used to measure
the amount of non-entrapped Rh B by spectrophotometric
analysis.
Nanoparticles Characterization
Particles size measurements and distribution were determined by
DLS analyzer (DLS/NanoBrook 90 Plus Particle Size Analyzer –
Brookhaven) at 25◦C. The PLGA NPs were dispersed in double
distilled water and analyzed in triplicates with three readings per
nanoparticle sample. The polydispersity was calculated based on
the volumetric distribution of particles. The NPs zeta potential
was measured by DLS (Zetasizer Malvern ZPS) at 25◦C.
The NPs morphology and size were observed by scanning
electron microscope (Mira Tescan) operated at 30 kV of beam
energy. A drop of the sample was deposited and spread at the
center of the carbon tape. After drying, the sample was sputter
coated with 2 nm gold.
Determination of Rhodamine B
Encapsulation Efficiency
The amount of Rh B trapped in the NPs was determined by
subtracting the amount of Rh B, present in the supernatant of the
nanoparticle suspension removed after centrifugation combined
to the supernatants collected during the cycles of nanoparticle
washes, from the initial quantity of Rh B used for nanoparticle
preparation. The Rh B in the supernatant was measured
using fluorescence spectrometry (λexcitation = 553 nm,
λemission= 574 nm). The non-encapsulated Rh B concentration
Frontiers in Pharmacology | www.frontiersin.org 2 December 2016 | Volume 7 | Article 458
fphar-07-00458 December 2, 2016 Time: 15:36 # 3
Jonderian and Maalouf Nanoparticles Interaction with Cardiomyocytes
was determined using a calibration curve. The EE was determined
as follow:
Amount of encapsulated Rh B =
Initial Rh B amount used for the preparation−
Amount of Rh B in the combined supernatants
Encapsulation efficiency (%) =
Amount of encapsulated Rh B
Initial Rh B amount used for the preparation
× 100
In vitro Release
The dialysis diffusion technique was used to evaluate Rh B release
from PLGA NPs. Briefly, 2.5 mg of the lyophilized PLGA NPs
were suspended in 500 µl PBS solution (PBS, 0.01 M) “inner
phase” and poured in a dialysis bag (molecular weight cut-off:
1,000 Da). The dialysis bag was emerged into 35 ml PBS buffer
“outer phase” with continuous stirring and was kept at 37◦C. Four
hundred microliter samples were pipetted from the outer phase
at different time intervals and were replaced with same volume
of fresh PBS. The experiments were performed in triplicate at
pH 7.2. The amount of Rh B released was quantified using high
performance liquid chromatography with fluorescence detector
(λexcitation= 539 nm, λemission= 573 nm).
Studies of Nanoparticles- Cardiac
Myocytes Interaction In vitro
In vitro experiments were performed to elucidate the interaction
of PLGA NPs with cardiac myocytes.
The cytotoxicity assessment of the RhoB-loaded PLGA NPs
was performed using the MTT assay (Gomez et al., 1997; Fajardo
et al., 2006). Approximately 1 × 105 cells/mL of cardiomyocytes
in their exponential growth phase were seeded in a flat-bottomed
96-well polystyrene coated plate and were incubated for 24 h at
37◦C in a 5% CO2 incubator. Different concentrations of NPs
were added to the plate. HG, known to induce cardiomyotoxicity
was used as a positive control (Kobayashi et al., 2012) and
mannitol, as a negative control. After 20 and 44 h of incubation,
10 µL of MTT reagent was added to each well and was further
incubated for 4 h. Formazan crystals formed after 4 h in each
well were dissolved in 150 µL of detergent and the plates were
read immediately in a microplate reader at 570 nm. Wells with
complete medium, NPs and MTT reagent, without cells were
used as blanks.
Cellular apoptosis was assessed using the cellular DNA
fragmentation test on cultured cardiomyocytes treated with
different concentration of the RhoB-loaded PLGA NPs. HG,
known to induce apoptosis, was used as a positive control and
mannitol was added to the experiments to serve as a negative
control. The test was performed using a commercial ELISA
that detects 178 BrdU-labeled DNA fragments according to the
manufacturer protocol (Roche Diagnostics).
The kinetic cellular uptake of RhB-loaded PLGA NPs was
assessed by confocal laser scanning microscopy (CLSM, Zeis
LSM 710). Cells were grown on coverslips in a 6-well tissue
culture plate at a concentration of 5 × 104 cells/well. Cells were
incubated at 37◦C under 5% CO2 and were maintained in a rat
cardiac myocyte growth medium supplied by the manufacturer
as described in the material and method section. Cells were
incubated with RhB-loaded PLGA NPs at a concentration of
200 ng/mL for 1, 6, 12, and 24 h, respectively. Afterward, they
were washed with PBS and fixed with 5% paraformaldehyde in
PBS. Canadian Balsam was dropped on the slides to seal the cell
samples after PBS washes. DAPI was used to stain the cells’ nuclei
in blue. Quantification of cellular uptake was based on a modified
method previously described by Blechinger et al. (2013). In brief,
and in order to determine the number of particles forming each
object the total intensity of particles or agglomerates is measured
and compared to the intensity of a single particle using image J.
Statistical Analysis
Results are expressed as means± standard errors (SE). Statistical
significance was assessed by the Student’s t-test with Prism 6
software (GraphPad Software). Significance was determined as a
probability (P value) of less than 0.05.
RESULTS AND DISCUSSION
Optimization of the PLGA Nanoparticles
Parameters
Experimental parameters such as the sonication time, PVA
concentration and organic to aqueous phase ratio were
investigated for particle size, PDI and EE. The results are
summarized in Table 1. All the experiments were conducted
by varying one parameter and keeping all the other processing
parameters constant.
The external energy applied via sonication is a crucial step
in the emulsification process. It will allow the breakdown of
the emulsion causing a decrease in the mean diameter of NPs.
An increase in the sonication time from 3 to 10 min leads to
a decrease in the mean diameter of NPs from 204 to 184 nm.
Sonication caused no considerable change in the PDI. The EE
exhibited a slight upward trend with increasing sonication. Thus,
a stable formulation was achieved after 10 min sonication with an
average diameter of 184 nm.
The PVA is a common stabilizer used to prevent the
aggregation of PLGA NPs. The effect of PVA on nanoparticle size
has been somewhat controversial. In some papers, the diameter
of the PLGA NPs was found to decrease with the increase of the
PVA concentration (Lee et al., 1999; Mainardes and Evangelista,
2005; Budhian et al., 2007) in others an opposite trend was
observed (Agrahari et al., 2009). Some researchers reported that
as the PVA concentration is increased, the mean diameter of
NPs first decreases and then gradually increases (Budhian et al.,
2007). In our case, we observed that the mean size of PLGA NPs
decreased with increasing PVA concentration from 0.5 to 2.5%
(w/v). The surfactant exerts its stabilizing effect by adsorbing
at the NPs interface, thus reducing the surface tension between
the two phases, preventing the aggregation of NPs and thereby
lowering their size. It is well known that PVA remains associated
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TABLE 1 | Comparison of particle size, PDI and EE of Rho-loaded PLGA
NPs prepared by varying different parameters.
Sonication
time (min)
Mean
diameter (nm)
PDI EE
(% ± SD)
Influence of sonication time
3 204 ± 12 0.18± 0.01 17 ± 10.41
5 190 ± 12 0.19± 0.03 25 ± 12.01
10 184 ± 7 0.19± 0.01 40 ± 2.94
PVA content
(% w/v)
Mean
diameter (nm)
PDI EE
(% ± SD)
Influence of PVA content
0.5 229 ± 17 0.22± 0.03 72 ± 4.58
1 222 ± 5 0.23± 0.02 65.5 ± 1.91
2.5 184 ± 7 0.19± 0.01 40 ± 2.94
org/aq Mean
diameter (nm)
PDI EE
(% ± SD)
Influence of organic to aqueous phase volume
0.5:10 232 ± 12 0.24± 0.01 50.25± 1.71
1:10 184 ± 7 0.19± 0.01 40± 2.94
2:10 195 ± 7 0.23± 0.01 34.5± 2.52
PDI, polydispersity index; EE, encapsulation efficiency. Values are presented as
mean ± standard deviation, n = 3.
at the surface of the polymer and is difficult to remove even
after successive washing. Sahoo et al. (2002) reported that NPs
with higher amount of residual PVA has relatively lower cellular
uptake. For instance, a 2.5% w/v was adopted and no attempts
were made to increase further the PVA concentration. The PDI
remained unchanged while passing from 0.5 to 1% PVA then
decreased with the increase of PVA to 2.5%. It was also observed
that an increase of the PVA concentration is accompanied by a
decrease in the EE.
The organic to aqueous phase ratio is another factor that can
impact the evaporation phase and the NPs formation process. The
size of the NPs exhibited an initial decrease from 232 to 184 nm
when the concentration of the organic phase increased from
4.76 to 9.09% by changing the ratio of the organic to aqueous
phase from 0.5:10 to 1:10 (v/v), respectively. The increase in
the organic phase volume prevents the coalescence of NPs and
lead to the decrease in the mean diameter. On further increasing
the concentration from 9.09 to 16.67%, a slight increase in the
particle size from 184 to 195 nm was observed. This finding may
be explained by the increase in the viscosity of the emulsion
formed implying a lower net shear stress, therefore leading to
the formation of larger size NPs. An optimum ratio of 1:10
was selected. The polydispersity decreased then increased by
changing the concentration of the organic phase from 4.76 to
9.09% and 16.675, respectively. The EE decreased as the volume
of the organic phase increases from 4.76 to 16.67%. This can be
explained by the fact that increasing the solvent volume increases
the time of solvent evaporation allowing more time for drug
diffusion and decreases the drug content.
The zeta potential is another important parameter considered
as a key indicator for the stability of nanoparticle in water
FIGURE 1 | Scanning electron micrograph of RhB-loaded PLGA NPs.
FIGURE 2 | Release profile of Rh B from PLGA NPs in phosphate
buffered saline (PBS) solution at 37◦C using dialysis method. Data
points are presented as mean ± standard deviation, n = 3.
suspension. The zeta potential of the optimized RhB-loaded
PLGA NPs was −21.7 ± 5.64 mV. Thus, the repulsion among
the negatively charged NPs provides stability and prevents
aggregation (Honary and Zahir, 2013).
The morphological properties and the size of the NPs were
characterized by SEM. PLGA NPs were found to have an average
diameter of 84.31 ± 9.31 nm with a smooth and spherical
surface morphology (Figure 1). There is often a discrepancy
between DLS and SEM measurements that is attributed to the
hydrodynamic radius calculated via DLS and the estimated of
projected area diameter obtained using SEM.
In vitro Release
The release profile of RhB-loaded PLGA NPs was measured at pH
7.4 and found to follow a biphasic pattern; a burst release followed
by a slower release rate. As shown in Figure 2, the release profile
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FIGURE 3 | (A) Cytotoxicity analyses results by MTT assay after 24 and 48 h
incubation with RhB-loaded PLGA NPs. (B) % of cardiomyocyte apoptosis
after 24 and 48 h incubation with RhB-loaded PLGA NPs as assessed by the
cellular DNA fragmentation assay. Values are the mean ± standard deviation
from three independent experiments. ∗P < 0.05 vs. normal glucose.
FIGURE 4 | Confocal fluorescence image showing cardiac myocytes
exposed to 200 ng/mL RhB-loaded PLGA NPs over different time
period. The blue color presents the nucleus stained with DAPI.
was recorded over a 3-day period. In the first stage, 29% of the Rh
B was released within the first 8 h. This initial burst release may
be attributed to the Rh B molecules adsorbed or encapsulated
close to the surface (Magenheim et al., 1993; Budhian et al.,
FIGURE 5 | Uptake kinetics of RhB-loaded PLGA NPs. Within the 24 h
the mean number of internalized NPs in cardiomyocytes increases significantly
and almost linearly. Results are statistically different (∗p < 0.05; ∗∗p < 0.01) for
time points 1–24 h. Results are expressed as mean ± standard deviation,
n = 3.
2008). The slower second phase is related to the entrapped Rh B
inside the polymeric NPs. Analogous release profile was observed
previously for PLGA NPs (Cartiera et al., 2009; Abulateefeh et al.,
2013).
Cytotoxicity and Confocal Microscopy
The cytotoxicity profile of the NPs was conducted using the MTT
assay. Only cells that are viable after 24 or 48 h exposed to
different concentration of NPs were capable of metabolizing a dye
[3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyl tetrazolium bromide]
efficiently and the purple colored precipitate which is dissolved
in a detergent was analyzed spectrophotometrically. Our results
show that cardiomyocyte cultured cells exposed to 20 mM HG
for 24 and 48 h undergo cell death assessed by the decrease in
the cellular viability assay. Mannitol, an osmotic control, and
as expected (Eid et al., 2009, 2013) did not show any effect
on cardiomyocyte survival/toxicity ruling out an osmotic effect.
The same profile of cardiomyocyte survival was obtained by
assessing cellular apoptosis using the cellular DNA fragmentation
assay. These results were corroborated with previously published
data (Duffy et al., 2006). Importantly our results show that no
significant cytotoxic or apoptotic effects were observed after 24 h
of exposure to 100, 200, and 400 µg/mL of RhB-loaded PLGA
NPs. Cells treated with the highest concentration of NPs showed
significantly low viability when compared to cells treated with
mannitol. On the other hand, 48 h of exposure to 400 and
600 µg/mL led to a significant decrease in cardiomyocyte viability
and an increase in cellular apoptosis (p < 0.05). Thus, it can
be concluded that cell viability decreases when exposure time
increases and that concentrations up to 200µg/mL do not possess
any significant cytotoxic or apoptotic effect after 24 and 48 h of
exposure (Figures 3A,B).
The kinetic uptake of RhoB-loaded PLGA NPs is a crucial
factor to study the interaction between NPs and cells. Figure 4
shows representative images of cardiac myocytes exposed to
200 ng/mL RhB-loaded PLGA NPs at different incubation time
points of 1, 6, 12, and 24 h. Quantification is based on a modified
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method previously described (Blechinger et al., 2013). In brief,
and in order to determine the number of particles forming each
object the total intensity of particles or agglomerates is measured
and compared to the intensity of a single particle using image J.
Figure 4 clearly demonstrates that NPs (red) are localized within
the cellular boundaries showing their uptake into the cytoplasm.
The NPs were distributed more or less regularly throughout the
cell and the cellular uptake appeared to increase with exposure
time from 1 to 24 h. Around 20 cardiac cells were analyzed
per time point applying the same controlled conditions. The
average fluorescence intensities at each time point are presented
in Figure 5. In fact, these results are in line with what was
described by Cartiera et al. (2009) whereby showed that the rate
and extent of PLGA NPs uptake among cell lines differs, most
likely due to regulatory mechanisms inherent to the particular cell
type.
CONCLUSION
In this present work, PLGA NPs loaded with the fluorescent agent
Rh B were prepared using single emulsion solvent evaporation
technique. Spherical particles with a diameter of 184 nm and 40%
EE were obtained. Release studies revealed that 29% of Rh B was
release within the first 8 h. These NPs were designed as models
to study their interactions with cardiac myocytes. No significant
in vitro cytotoxic effect was observed in cardiac myocytes after
24 and 48 h of exposure to 100 and 200 µg/mL consecutively.
Cells exposed to 400 µg/mL of RhB-loaded PLGA NPs showed
decrease in cell viability after 48 h of exposure, an effect not seen
after 24 h of exposure at the same concentration. Furthermore,
the confocal images demonstrate that PLGA NPs are taken
up intracellularly. These findings, all together, make these NPs
good candidate for future targeted siRNA delivery for cardiac
myocytes, making it possible to deliver drugs, inhibitors and
other therapeutic proteins to local areas of disease to maximize
clinical benefit while limiting unwanted side effects.
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